After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. T...
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...